These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 15354286)

  • 21. From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative.
    Verma AM; Patel A; Subramanian S; Smith PJ
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):88-89. PubMed ID: 33444534
    [No Abstract]   [Full Text] [Related]  

  • 22. [Biological drugs in inflammatory bowel disease: Management and care].
    Guerra I; Bermejo F
    Rev Esp Enferm Dig; 2015 Jul; 107(7):454. PubMed ID: 26140643
    [No Abstract]   [Full Text] [Related]  

  • 23. Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening.
    Jauregui-Amezaga A; Turon F; Ordás I; Gallego M; Feu F; Ricart E; Panés J
    J Crohns Colitis; 2013 Apr; 7(3):208-12. PubMed ID: 22677117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Infliximab: getting the most for your money.
    Irving PM; Gibson PR
    J Gastroenterol Hepatol; 2007 Oct; 22(10):1559-61. PubMed ID: 17845681
    [No Abstract]   [Full Text] [Related]  

  • 25. Infliximab therapy in children and adolescents with inflammatory bowel disease.
    Veres G; Baldassano RN; Mamula P
    Drugs; 2007; 67(12):1703-23. PubMed ID: 17683171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Perspectives in inflammatory bowel diseases treatment].
    Jalocha L; Wojtuń S; Dyrla P; Błaszak A; Wojtkowiak M; Zyśko B; Stelmaszuk T; Gil J
    Pol Merkur Lekarski; 2009 May; 26(155):556-8. PubMed ID: 19606725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
    Ben-Horin S; Heap GA; Ahmad T; Kim H; Kwon T; Chowers Y
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():27-34. PubMed ID: 26395532
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alpha 4 integrin blockade in inflammatory bowel disease.
    Ghosh S
    Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii70-2. PubMed ID: 14532154
    [No Abstract]   [Full Text] [Related]  

  • 29. Variation in infliximab administration practices in the treatment of pediatric inflammatory bowel disease.
    Adler J; Sandberg KC; Shpeen BH; Eder SJ; Dhanani M; Clark SJ; Freed GL
    J Pediatr Gastroenterol Nutr; 2013 Jul; 57(1):35-8. PubMed ID: 23459317
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term safety of Infliximab for the treatment of inflammatory bowel disease: does blocking TNFalpha reduce colitis-associated colorectal carcinogenesis?
    Biancone L; Petruzziello C; Calabrese E; Zorzi F; Naccarato P; Onali S; Pallone F
    Gut; 2009 Dec; 58(12):1703. PubMed ID: 19923350
    [No Abstract]   [Full Text] [Related]  

  • 31. Unusual presentation of tuberculosis after infliximab therapy.
    Magro F; Pereira P; Veloso FT; Carneiro F
    Inflamm Bowel Dis; 2005 Jan; 11(1):82-4. PubMed ID: 15674123
    [No Abstract]   [Full Text] [Related]  

  • 32. Selection of skin test antigens to evaluate PPD anergy.
    Wright PW; Crutcher JE; Holiday DB
    J Fam Pract; 1995 Jul; 41(1):59-64. PubMed ID: 7798066
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evolutionary biologic therapy for inflammatory bowel disease.
    Hanauer SB
    Curr Gastroenterol Rep; 1999 Dec; 1(6):467-9. PubMed ID: 10980987
    [No Abstract]   [Full Text] [Related]  

  • 34. [New inflammatory bowel disease drugs targeting the inflammatory cascade].
    Desreumaux P
    Gastroenterol Clin Biol; 2001 Apr; 25(4 Suppl):B72-8. PubMed ID: 11449147
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical and scientific aspects related to biosimilars in inflammatory bowel diseases (IBD): position document of the Belgian IBD Research & Development Group (BIRD).
    Vermeire S; Louis E; Dewit O; Franchimont D; Moreels T; Ferrante M; Rahier JF; Van Hootegem P; De Vos M; Mana F; Baert F;
    Acta Gastroenterol Belg; 2015; 78(1):26-9. PubMed ID: 26118575
    [No Abstract]   [Full Text] [Related]  

  • 36. Can Subcutaneous Infliximab Replace Dose-Intensified Intravenous Administration in Inflammatory Bowel Disease?
    Little RD; Ward MG; Sparrow MP
    Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2430-2431. PubMed ID: 36155249
    [No Abstract]   [Full Text] [Related]  

  • 37. [TNF-alpha inhibitors in inflammatory bowel disease].
    Casellas i Jordà F
    Med Clin (Barc); 2004 Nov; 123(16):627-34. PubMed ID: 15546523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Severe adverse reactions to Infliximab therapy are common in young children with inflammatory bowel disease.
    Kolho KL; Ruuska T; Savilahti E
    Acta Paediatr; 2007 Jan; 96(1):128-30. PubMed ID: 17187619
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Miliary tuberculosis in a patient with Crohn's disease].
    Ferrer I; Maroto N; Montón C; Villagrasa R; López A; Clofent J; Hinojosa J
    Gastroenterol Hepatol; 2011; 34(7):511-3. PubMed ID: 21737181
    [No Abstract]   [Full Text] [Related]  

  • 40. [Application of TNF-alpha blocker concentration assays in the treatment of inflammatory bowel diseases].
    Sipponen T; Kolho KL
    Duodecim; 2013; 129(5):499-505. PubMed ID: 23520893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.